Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
To improve transparency and encourage the development and submission of ANDAs for drugs with limited competition, FDA has published a list of approved NDA products that are off-patent and off-exclusivity, and for which the FDA has not approved an ANDA referencing that NDA drug product. The list is based on the Orange Book Data Files as of April 13, 2018.
[/membership]
